CN112010965B - 一种针对新冠病毒SARS-CoV-2棘突蛋白RBD区的单克隆抗体及其应用 - Google Patents
一种针对新冠病毒SARS-CoV-2棘突蛋白RBD区的单克隆抗体及其应用 Download PDFInfo
- Publication number
- CN112010965B CN112010965B CN202010926533.8A CN202010926533A CN112010965B CN 112010965 B CN112010965 B CN 112010965B CN 202010926533 A CN202010926533 A CN 202010926533A CN 112010965 B CN112010965 B CN 112010965B
- Authority
- CN
- China
- Prior art keywords
- cov
- monoclonal antibody
- novel coronavirus
- seq
- coronavirus sars
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241001678559 COVID-19 virus Species 0.000 title claims abstract description 47
- 238000000034 method Methods 0.000 title claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 11
- 206010035664 Pneumonia Diseases 0.000 claims abstract description 10
- 238000001514 detection method Methods 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 239000013604 expression vector Substances 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 230000008105 immune reaction Effects 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 241000711573 Coronaviridae Species 0.000 abstract description 23
- 231100000419 toxicity Toxicity 0.000 abstract description 4
- 230000001988 toxicity Effects 0.000 abstract description 4
- 239000000243 solution Substances 0.000 description 44
- 108090000623 proteins and genes Proteins 0.000 description 23
- 238000002965 ELISA Methods 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 18
- 102100031673 Corneodesmosin Human genes 0.000 description 17
- 101710139375 Corneodesmosin Proteins 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 238000002835 absorbance Methods 0.000 description 14
- 238000005406 washing Methods 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 101001028244 Onchocerca volvulus Fatty-acid and retinol-binding protein 1 Proteins 0.000 description 10
- 238000002823 phage display Methods 0.000 description 10
- 241000700605 Viruses Species 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 9
- 238000010586 diagram Methods 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 8
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 6
- 229960000723 ampicillin Drugs 0.000 description 6
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 238000004091 panning Methods 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 235000020183 skimmed milk Nutrition 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 229930027917 kanamycin Natural products 0.000 description 4
- 229960000318 kanamycin Drugs 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 229930182823 kanamycin A Natural products 0.000 description 4
- 239000012460 protein solution Substances 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 3
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 3
- 101710091045 Envelope protein Proteins 0.000 description 3
- 102100034349 Integrase Human genes 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 229940096437 Protein S Drugs 0.000 description 3
- 101710188315 Protein X Proteins 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- SDZRIBWEVVRDQI-CIUDSAMLSA-N Ala-Lys-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O SDZRIBWEVVRDQI-CIUDSAMLSA-N 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 101710094648 Coat protein Proteins 0.000 description 2
- 108091029865 Exogenous DNA Proteins 0.000 description 2
- WNZOCXUOGVYYBJ-CDMKHQONSA-N Gly-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CN)O WNZOCXUOGVYYBJ-CDMKHQONSA-N 0.000 description 2
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- 102000011931 Nucleoproteins Human genes 0.000 description 2
- 108010061100 Nucleoproteins Proteins 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- CUMXHKAOHNWRFQ-BZSNNMDCSA-N Phe-Asp-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 CUMXHKAOHNWRFQ-BZSNNMDCSA-N 0.000 description 2
- MCIXMYKSPQUMJG-SRVKXCTJSA-N Phe-Ser-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MCIXMYKSPQUMJG-SRVKXCTJSA-N 0.000 description 2
- 101710083689 Probable capsid protein Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 101710198474 Spike protein Proteins 0.000 description 2
- XDARBNMYXKUFOJ-GSSVUCPTSA-N Thr-Asp-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XDARBNMYXKUFOJ-GSSVUCPTSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
- BUDNAJYVCUHLSV-ZLUOBGJFSA-N Ala-Asp-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O BUDNAJYVCUHLSV-ZLUOBGJFSA-N 0.000 description 1
- AWNAEZICPNGAJK-FXQIFTODSA-N Ala-Met-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(O)=O AWNAEZICPNGAJK-FXQIFTODSA-N 0.000 description 1
- NCQMBSJGJMYKCK-ZLUOBGJFSA-N Ala-Ser-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O NCQMBSJGJMYKCK-ZLUOBGJFSA-N 0.000 description 1
- ARHJJAAWNWOACN-FXQIFTODSA-N Ala-Ser-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O ARHJJAAWNWOACN-FXQIFTODSA-N 0.000 description 1
- CREYEAPXISDKSB-FQPOAREZSA-N Ala-Thr-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CREYEAPXISDKSB-FQPOAREZSA-N 0.000 description 1
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 1
- VKKYFICVTYKFIO-CIUDSAMLSA-N Arg-Ala-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N VKKYFICVTYKFIO-CIUDSAMLSA-N 0.000 description 1
- AOHKLEBWKMKITA-IHRRRGAJSA-N Arg-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N AOHKLEBWKMKITA-IHRRRGAJSA-N 0.000 description 1
- MKJBPDLENBUHQU-CIUDSAMLSA-N Asn-Ser-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O MKJBPDLENBUHQU-CIUDSAMLSA-N 0.000 description 1
- UGXYFDQFLVCDFC-CIUDSAMLSA-N Asn-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O UGXYFDQFLVCDFC-CIUDSAMLSA-N 0.000 description 1
- SNYCNNPOFYBCEK-ZLUOBGJFSA-N Asn-Ser-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O SNYCNNPOFYBCEK-ZLUOBGJFSA-N 0.000 description 1
- JBDLMLZNDRLDIX-HJGDQZAQSA-N Asn-Thr-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O JBDLMLZNDRLDIX-HJGDQZAQSA-N 0.000 description 1
- XYBJLTKSGFBLCS-QXEWZRGKSA-N Asp-Arg-Val Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC(O)=O XYBJLTKSGFBLCS-QXEWZRGKSA-N 0.000 description 1
- QNFRBNZGVVKBNJ-PEFMBERDSA-N Asp-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)O)N QNFRBNZGVVKBNJ-PEFMBERDSA-N 0.000 description 1
- MNQMTYSEKZHIDF-GCJQMDKQSA-N Asp-Thr-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O MNQMTYSEKZHIDF-GCJQMDKQSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000008904 Betacoronavirus Species 0.000 description 1
- 229940022962 COVID-19 vaccine Drugs 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- SZQCDCKIGWQAQN-FXQIFTODSA-N Cys-Arg-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O SZQCDCKIGWQAQN-FXQIFTODSA-N 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- WUAYFMZULZDSLB-ACZMJKKPSA-N Gln-Ala-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O WUAYFMZULZDSLB-ACZMJKKPSA-N 0.000 description 1
- OYTPNWYZORARHL-XHNCKOQMSA-N Gln-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N OYTPNWYZORARHL-XHNCKOQMSA-N 0.000 description 1
- LPYPANUXJGFMGV-FXQIFTODSA-N Gln-Gln-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)N LPYPANUXJGFMGV-FXQIFTODSA-N 0.000 description 1
- JXFLPKSDLDEOQK-JHEQGTHGSA-N Gln-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O JXFLPKSDLDEOQK-JHEQGTHGSA-N 0.000 description 1
- FQCILXROGNOZON-YUMQZZPRSA-N Gln-Pro-Gly Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O FQCILXROGNOZON-YUMQZZPRSA-N 0.000 description 1
- OSCLNNWLKKIQJM-WDSKDSINSA-N Gln-Ser-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O OSCLNNWLKKIQJM-WDSKDSINSA-N 0.000 description 1
- SXFPZRRVWSUYII-KBIXCLLPSA-N Gln-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)N)N SXFPZRRVWSUYII-KBIXCLLPSA-N 0.000 description 1
- PAQUJCSYVIBPLC-AVGNSLFASA-N Glu-Asp-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PAQUJCSYVIBPLC-AVGNSLFASA-N 0.000 description 1
- YQPFCZVKMUVZIN-AUTRQRHGSA-N Glu-Val-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQPFCZVKMUVZIN-AUTRQRHGSA-N 0.000 description 1
- MIIVFRCYJABHTQ-ONGXEEELSA-N Gly-Leu-Val Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O MIIVFRCYJABHTQ-ONGXEEELSA-N 0.000 description 1
- PDUHNKAFQXQNLH-ZETCQYMHSA-N Gly-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)NCC(O)=O PDUHNKAFQXQNLH-ZETCQYMHSA-N 0.000 description 1
- NVTPVQLIZCOJFK-FOHZUACHSA-N Gly-Thr-Asp Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O NVTPVQLIZCOJFK-FOHZUACHSA-N 0.000 description 1
- ZZWUYQXMIFTIIY-WEDXCCLWSA-N Gly-Thr-Leu Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O ZZWUYQXMIFTIIY-WEDXCCLWSA-N 0.000 description 1
- NGBGZCUWFVVJKC-IRXDYDNUSA-N Gly-Tyr-Tyr Chemical compound C([C@H](NC(=O)CN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 NGBGZCUWFVVJKC-IRXDYDNUSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- HDOYNXLPTRQLAD-JBDRJPRFSA-N Ile-Ala-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)O)N HDOYNXLPTRQLAD-JBDRJPRFSA-N 0.000 description 1
- NZGTYCMLUGYMCV-XUXIUFHCSA-N Ile-Lys-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N NZGTYCMLUGYMCV-XUXIUFHCSA-N 0.000 description 1
- PXKACEXYLPBMAD-JBDRJPRFSA-N Ile-Ser-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PXKACEXYLPBMAD-JBDRJPRFSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 1
- OFFWOVJBSQMVPI-RMLGOCCBSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O.N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 OFFWOVJBSQMVPI-RMLGOCCBSA-N 0.000 description 1
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 1
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 1
- 239000012880 LB liquid culture medium Substances 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- USTCFDAQCLDPBD-XIRDDKMYSA-N Leu-Asn-Trp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N USTCFDAQCLDPBD-XIRDDKMYSA-N 0.000 description 1
- AXZGZMGRBDQTEY-SRVKXCTJSA-N Leu-Gln-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O AXZGZMGRBDQTEY-SRVKXCTJSA-N 0.000 description 1
- CQGSYZCULZMEDE-UHFFFAOYSA-N Leu-Gln-Pro Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)N1CCCC1C(O)=O CQGSYZCULZMEDE-UHFFFAOYSA-N 0.000 description 1
- FEHQLKKBVJHSEC-SZMVWBNQSA-N Leu-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FEHQLKKBVJHSEC-SZMVWBNQSA-N 0.000 description 1
- QNBVTHNJGCOVFA-AVGNSLFASA-N Leu-Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O QNBVTHNJGCOVFA-AVGNSLFASA-N 0.000 description 1
- KIZIOFNVSOSKJI-CIUDSAMLSA-N Leu-Ser-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N KIZIOFNVSOSKJI-CIUDSAMLSA-N 0.000 description 1
- IXHKPDJKKCUKHS-GARJFASQSA-N Lys-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N IXHKPDJKKCUKHS-GARJFASQSA-N 0.000 description 1
- GQZMPWBZQALKJO-UWVGGRQHSA-N Lys-Gly-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O GQZMPWBZQALKJO-UWVGGRQHSA-N 0.000 description 1
- AIRZWUMAHCDDHR-KKUMJFAQSA-N Lys-Leu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O AIRZWUMAHCDDHR-KKUMJFAQSA-N 0.000 description 1
- PDIDTSZKKFEDMB-UWVGGRQHSA-N Lys-Pro-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O PDIDTSZKKFEDMB-UWVGGRQHSA-N 0.000 description 1
- UGCIQUYEJIEHKX-GVXVVHGQSA-N Lys-Val-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O UGCIQUYEJIEHKX-GVXVVHGQSA-N 0.000 description 1
- SPSSJSICDYYTQN-HJGDQZAQSA-N Met-Thr-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O SPSSJSICDYYTQN-HJGDQZAQSA-N 0.000 description 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- FGWUALWGCZJQDJ-URLPEUOOSA-N Phe-Thr-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FGWUALWGCZJQDJ-URLPEUOOSA-N 0.000 description 1
- KLYYKKGCPOGDPE-OEAJRASXSA-N Phe-Thr-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O KLYYKKGCPOGDPE-OEAJRASXSA-N 0.000 description 1
- KWMZPPWYBVZIER-XGEHTFHBSA-N Pro-Ser-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KWMZPPWYBVZIER-XGEHTFHBSA-N 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- 108091005634 SARS-CoV-2 receptor-binding domains Proteins 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- WTWGOQRNRFHFQD-JBDRJPRFSA-N Ser-Ala-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WTWGOQRNRFHFQD-JBDRJPRFSA-N 0.000 description 1
- QEDMOZUJTGEIBF-FXQIFTODSA-N Ser-Arg-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O QEDMOZUJTGEIBF-FXQIFTODSA-N 0.000 description 1
- FMDHKPRACUXATF-ACZMJKKPSA-N Ser-Gln-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O FMDHKPRACUXATF-ACZMJKKPSA-N 0.000 description 1
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 1
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 1
- OQPNSDWGAMFJNU-QWRGUYRKSA-N Ser-Gly-Tyr Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 OQPNSDWGAMFJNU-QWRGUYRKSA-N 0.000 description 1
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 1
- GJFYFGOEWLDQGW-GUBZILKMSA-N Ser-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)N GJFYFGOEWLDQGW-GUBZILKMSA-N 0.000 description 1
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 1
- AZWNCEBQZXELEZ-FXQIFTODSA-N Ser-Pro-Ser Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O AZWNCEBQZXELEZ-FXQIFTODSA-N 0.000 description 1
- CUXJENOFJXOSOZ-BIIVOSGPSA-N Ser-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CO)N)C(=O)O CUXJENOFJXOSOZ-BIIVOSGPSA-N 0.000 description 1
- OLKICIBQRVSQMA-SRVKXCTJSA-N Ser-Ser-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OLKICIBQRVSQMA-SRVKXCTJSA-N 0.000 description 1
- NADLKBTYNKUJEP-KATARQTJSA-N Ser-Thr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O NADLKBTYNKUJEP-KATARQTJSA-N 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- FQPDRTDDEZXCEC-SVSWQMSJSA-N Thr-Ile-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O FQPDRTDDEZXCEC-SVSWQMSJSA-N 0.000 description 1
- GXUWHVZYDAHFSV-FLBSBUHZSA-N Thr-Ile-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GXUWHVZYDAHFSV-FLBSBUHZSA-N 0.000 description 1
- BIBYEFRASCNLAA-CDMKHQONSA-N Thr-Phe-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 BIBYEFRASCNLAA-CDMKHQONSA-N 0.000 description 1
- HUPLKEHTTQBXSC-YJRXYDGGSA-N Thr-Ser-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HUPLKEHTTQBXSC-YJRXYDGGSA-N 0.000 description 1
- MNYNCKZAEIAONY-XGEHTFHBSA-N Thr-Val-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O MNYNCKZAEIAONY-XGEHTFHBSA-N 0.000 description 1
- SVGAWGVHFIYAEE-JSGCOSHPSA-N Trp-Gly-Gln Chemical compound C1=CC=C2C(C[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)=CNC2=C1 SVGAWGVHFIYAEE-JSGCOSHPSA-N 0.000 description 1
- MBLJBGZWLHTJBH-SZMVWBNQSA-N Trp-Val-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 MBLJBGZWLHTJBH-SZMVWBNQSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- VCXWRWYFJLXITF-AUTRQRHGSA-N Tyr-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 VCXWRWYFJLXITF-AUTRQRHGSA-N 0.000 description 1
- QOIKZODVIPOPDD-AVGNSLFASA-N Tyr-Cys-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(O)=O QOIKZODVIPOPDD-AVGNSLFASA-N 0.000 description 1
- QUILOGWWLXMSAT-IHRRRGAJSA-N Tyr-Gln-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O QUILOGWWLXMSAT-IHRRRGAJSA-N 0.000 description 1
- SSYBNWFXCFNRFN-GUBZILKMSA-N Val-Pro-Ser Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O SSYBNWFXCFNRFN-GUBZILKMSA-N 0.000 description 1
- OWFGFHQMSBTKLX-UFYCRDLUSA-N Val-Tyr-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N OWFGFHQMSBTKLX-UFYCRDLUSA-N 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 description 1
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 1
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 108010008355 arginyl-glutamine Proteins 0.000 description 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000007499 fusion processing Methods 0.000 description 1
- 108010078144 glutaminyl-glycine Proteins 0.000 description 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 1
- 108010010147 glycylglutamine Proteins 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229960004525 lopinavir Drugs 0.000 description 1
- 229940120922 lopinavir and ritonavir Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 208000026425 severe pneumonia Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 108010044292 tryptophyltyrosine Proteins 0.000 description 1
- 108010003137 tyrosyltyrosine Proteins 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
Abstract
本发明公开了一种针对新冠病毒SARS‑CoV‑2的单克隆抗体及其应用,该单克隆抗体与新冠病毒SARS‑CoV‑2棘突蛋白RBD区特异性结合;在制备SARS‑CoV‑2检测产品、制备抑制SARS‑CoV‑2抗体药物和制备预防或治疗由SARS‑CoV‑2引起的肺炎的抗体药物制剂中均有广泛的应用前景;本发明的针对新冠病毒SARS‑CoV‑2的单克隆抗体,效价高、特异性强,可以高效表达,能与新冠病毒SARS‑CoV‑2表面的棘突蛋白RBD区特异性结合,可用于新冠病毒的检测,并且能够中和并减弱一定的新冠病毒毒性,起到预防或/和治疗新冠病毒肺炎的作用。
Description
技术领域
本发明涉及细胞免疫学、分子生物学技术领域,具体说是一种针对新冠病毒SARS-CoV-2棘突蛋白RBD区的单克隆抗体及其应用。
背景技术
SARS-CoV-2,属于冠状病毒科(Coronaviridae)、正冠状病毒亚科(Orthocoronavirinae)的β冠状病毒属(Coronavirus),与严重急性呼吸综合症相关冠状病毒(SARS-CoV)和中东呼吸综合征相关冠状病毒(MERS-CoV)近缘,都会导致严重肺炎症状。该病毒经飞沫、接触等途径传播,潜伏期患者即具备传播性。且研究发现,新冠肺炎患者在病程早期、症状轻微时即有极强的传染性。
SARS-CoV-2病毒直径为75-160纳米,其基因组为连续线性单链RNA,依次编码核蛋白(nucleoprotein)、包膜蛋白(envelope protein)、膜蛋白(membrane protein)及棘突蛋白(spike protein,又称S-protein或S蛋白),其中棘突蛋白是其表面最重要的蛋白,主要功能为决定病毒的宿主范围和特异性,与宿主细胞细胞膜受体结合并融合,实现对细胞的侵染。棘突蛋白包括S1和S2两个亚基,S1中的受体结合区(receptor binding domain,RBD),与人类SARS-CoV受体血管紧张素转化酶II(ACE2)分子互作,而S2则含有膜融合过程所需要的基本元件,实现病毒与细胞的融合。因此S蛋白的人源单克隆抗体理论上可以阻断病毒跟细胞的结合,具有减弱病毒传染的能力,可以作为抗体药物用于治疗新冠病毒肺炎患者。
抗体是哺乳动物免疫***中的一个重要糖蛋白分子。抗体分子由两条重链(Heavychain)和两条轻链(Light chain)组成,其中重链又分为可变区(Variable region ofheavy chain,VH)和三个恒定区(Constant region of heavy chain;CH1、CH2、CH3),轻链则由一个可变区(VL)和一个恒定区(CL)组成。可变区具有与抗原特异性结合的功能,因抗体个体不同呈现差异性,而抗体的恒定区则由抗体的种属及亚型决定。抗体重链可变区包含三个互补决定区(Complementarity-determining regions;CDRH1、CDRH2、CDRH3),轻链可变区也包含三个互补决定区,即CDRL1、CDRL2、和CDRL3,互补决定区又称高变区,直接与抗原表位结合。
各国针对新冠肺炎的治疗提出了多种治疗方案,但是目前并没有特异性针对新冠病毒的治疗药物或疫苗上市,抗新冠病毒药物主要有小分子药物瑞德西韦、氯喹与羟氯喹联用,洛匹那韦与利托那韦联用及洛匹那韦、利托那韦与干扰素的三药联用但都没有明显的治疗效果,有些药物甚至存在严重的毒副作用。抗体药物在传染病、自身免疫疾病及肿瘤等的治疗上发挥了重要作用,在当前面临的SARS-CoV-2疫苗开发困难且时期漫长、传统药物副作用大甚至没有效果的情况下,开发针对新冠病毒SARS-CoV-2的单克隆抗体具有非常重要的意义。
发明内容
为解决上述问题,本发明的目的是提供一种针对新冠病毒SARS-CoV-2棘突蛋白RBD区的单克隆抗体及其应用。
本发明为实现上述目的,通过以下技术方案实现:
一种针对新冠病毒SARS-CoV-2的单克隆抗体(A7),该单克隆抗体与新冠病毒SARS-CoV-2棘突蛋白RBD区特异性结合;包括重链可变区的互补性决定区域CDRH1、CDRH2、CDRH3和轻链可变区的互补性决定区域CDRL1、CDRL2、CDRL3;重链可变区的互补性决定区域CDRH1、CDRH2、CDRH3的氨基酸序列分别如SEQ ID NO:2、SEQ ID NO:3和SEQ ID NO:4所示;轻链可变区的互补性决定区域CDRL1、CDRL2、CDRL3的氨基酸序列分别如SEQ ID NO:6、SEQID NO:7和SEQ ID NO:8所示。
优选的一种针对新冠病毒SARS-CoV-2的单克隆抗体(A7),所述单克隆抗体的重链可变区的氨基酸序列为SEQ ID NO:1,所述单克隆抗体的轻链可变区的氨基酸序列为SEQID NO:5。
本发明还包括一种分离的核酸分子,所述核酸分子编码上述任一项所述的单克隆抗体(A7)。
本发明还包括一种包括上述的核酸分子的表达载体,除了前面所述的核酸分子之外,表达载体还包括与所述核酸分子序列操作性相连的表达调控序列。
表达载体是指可将编码A7抗体的多聚核苷酸***其中并使A7抗体得到表达的一种核酸运载工具。载体可通过转化、转导或转染宿主细胞,使其携带的遗传物质元件在宿主细胞内得以表达。载体的种类包括本领域熟知的细菌质粒、噬菌体、酵母质粒、植物细胞病毒、哺乳动物细胞病毒如腺病毒、逆转录病毒或其他载体。原则上,只要能在宿主体内复制和稳定,任何载体都可以用。在表达载体中,除了含有复制起点外,还可含有标记基因和其他翻译调控元件。
本发明还包括一种包括上述核酸分子或上述的表达载体的宿主细胞。
表达A7抗体的宿主细胞可以是原核细胞,如细菌细胞;或是低等真核细胞,如酵母细胞;或是高等真核细胞,如哺乳动物细胞。代表性例子有:大肠杆菌、链霉菌属;鼠伤寒沙门氏菌的细菌细胞;真菌细胞如酵母;植物细胞;果蝇S2或Sf9的昆虫细胞;CHO、COS、293细胞或Bowes黑素瘤细胞等动物细胞。
本发明还包括一种非诊断目的的检测新型冠状病毒SARS-CoV-2水平的方法,包括如下步骤:
①提取含有新型冠状病毒SARS-CoV-2的样品;
②将步骤①得到的样品与上述任一项所述的单克隆抗体接触;
③检测样品与抗体的免疫反应。
本发明还包括任一项针对新冠病毒SARS-CoV-2的单克隆抗体在制备新冠病毒SARS-CoV-2检测产品中的应用。
所述检测产品包括但不限于检测试剂、试剂盒、芯片或试纸。凡是包括前面所述结合分子的能够检测出SARS-CoV-2的检测产品均包括在本发明的范围之内。
本发明还包括任一项针对新冠病毒SARS-CoV-2的单克隆抗体在制备抑制新冠病毒SARS-CoV-2抗体药物中的应用。
本发明还包括任一项针对新冠病毒SARS-CoV-2的单克隆抗体在制备预防或治疗由新冠病毒SARS-CoV-2引起的肺炎的抗体药物制剂中的应用。
本发明所用的术语“新冠病毒SARS-CoV-2”与“SARS-CoV-2病毒”、“新冠病毒”“SARS-CoV-2”可以互换使用。
本发明所涉及的序列具体信息如下:
SEQ ID NO:1:
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAIASSGYYTSYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDTDTFDYWGQGTLVTVSS;
SEQ ID NO:2:
GFTFSSYA;
SEQ ID NO:3:
IASSGYYT;
SEQ ID NO:4:
AKDTDTFDY;
SEQ ID NO:5:
DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSSPSTFGQGTKVEIKR;
SEQ ID NO:6:
QSISSY;
SEQ ID NO:7:
AAS;
SEQ ID NO:8:
QQANSSPST;
本发明相比现有技术具有以下优点:
本发明的针对新冠病毒SARS-CoV-2的单克隆抗体,效价高、特异性强,可以高效表达,能与新冠病毒SARS-CoV-2表面的棘突蛋白RBD区特异性结合,可用于新冠病毒SARS-CoV-2的检测,并且能够中和并减弱一定的新冠病毒毒性,起到预防或/和治疗新冠病毒肺炎的目的。
噬菌体展示技术把外源DNA***噬菌体编码外壳蛋白的基因中,使外源DNA片断对应的表达产物融合在噬菌体的外壳蛋白中形成融合蛋白,呈现在噬菌体表面。具有如下显著的优点:建立了基因型和表型之间直接的物理联系,从而使筛选简便高效。本发明从合成抗体库Tomlinson I+J噬菌体展示抗体库中筛选到了一株能够跟新冠病毒SARS-CoV-2的S蛋白结合的抗体,该抗体在新冠病毒的检测及减弱病毒毒性方面具有重要的应用价值。
附图说明
图1为淘筛各步所得多克隆抗体酶联免疫吸附试验结果示意图;
图2为单克隆抗体酶联免疫吸附试验结果示意图;
图3为A7-Fab抗体片段聚丙烯酰胺凝胶电泳分析图;
图4为A7-Fab抗原特异性酶联免疫吸附试验原理示意图;
图5为A7-Fab的抗原特异性检测结果示意图;
图6为A7-Fab阻碍ACE2与RBD结合酶联免疫吸附试验原理示意图;
图7为A7-Fab阻碍ACE2与RBD结合的酶联免疫吸附试验结果。
具体实施方式
本发明的目的是提供一种针对新冠病毒SARS-CoV-2棘突蛋白RBD区的单克隆抗体及其应用,通过以下实施例进一步说明本发明。本发明的实施例用于说明而非限制,根据本发明的实质对其进行的简单改进都属于要求保护的范围。
实施例1
一、噬菌体展示抗体文库的扩增
将冷冻保存的0.5mL含有Tomlinson I+J噬菌体展示抗体库噬菌粒(英国MRC HGMP资源中心)的TG-1大肠杆菌冻存液融化后,加入25mL 2YT(1.6%Tryptone,1%YeastExtract,0.5%NaCl)培养基中培养至OD600为0.4,加入109cfu辅助噬菌体KM13,37℃感染1小时后,3000g离心30分钟,弃上清,用含有100μg/mL氨苄青霉素、50μg/mL卡那霉素及0.1%葡萄糖的2YT培养基50mL悬浮菌体,30℃、250rpm的速度摇菌16小时,次日5000g、30分钟离心培养液,分离回收上清40mL,在上清液中加入10mL的PEG/NaCl溶液,混合均匀后在冰上放置30分钟,5000g、30分钟离心、弃上清,加入2mL的灭菌PBS溶液将沉淀溶解,作为噬菌体展示抗体库溶液,利用大肠杆菌对噬菌体展示抗体库进行滴定,所制备抗体库的滴度1012cfu/mL。
二、噬菌体展示抗体库的淘筛
在96孔微孔板的10个孔内各加入100μL含有10μg/mL SARS-CoV-2病毒S1蛋白的PBS溶液,4℃过夜孵育,次日弃抗原溶液,每孔加入200μL含有2%脱脂奶粉的PBS溶液,25℃孵育2小时进行封闭,用PBST洗涤3次后,每孔加入100μL的噬菌体溶液(R0;每孔含有109cfu的噬菌体),室温下孵育2小时,用PBST洗涤后,每孔加入100μL的胰蛋白酶将结合到病毒S1蛋白的噬菌体洗脱。
培养TG-1大肠杆菌至OD600为0.4,取4mL菌液,将500μL溶出的噬菌体溶液加入到菌液中,37℃感染30分钟,5000g离心20分钟,弃上清,用含有100μg/mL氨苄青霉素、50μg/mL卡那霉素及0.1%葡萄糖的2YT培养基悬浮菌体,30℃、250rpm摇菌16小时;次日5000g、30分钟离心培养液,分离回收上清,在上清溶液中加入1/5容积的PEG/NaCl溶液,混合均匀后在冰上放置30分钟,5000g、30分钟离心,弃上清,加入200μL的灭菌PBS溶液,作为第一次富集后的噬菌体溶液(R1);重复以上步骤,分别获得噬菌体溶液R2和R3;执行酶联免疫吸附试验,验证淘筛过程中获得的噬菌体展示抗体库与新冠病毒S1蛋白的结合特异性及结合性能。
酶联免疫吸附试验的操作如下:在96孔酶标板内加入100μL新冠病毒S1蛋白溶液(2μg/mL)或牛血清白蛋白BSA(2μg/mL)的PBS溶液,4℃过夜,次日弃抗原溶液,加入200μL含有2%脱脂奶粉的溶液,在25℃下孵育2小时,对酶标板进行封闭。用含有0.1%吐温20的PBS溶液洗涤酶标板3次,加入稀释后的R0及R2噬菌体溶液(109cfu/well),25℃孵育1小时,用PBST溶液洗涤酶标板,加入HRP标记的小鼠抗M13抗体,孵育1小时后,用PBST洗板,加入HRP底物TMBZ(用pH6.0的乙酸钠溶液配制,含1/10000稀释的30%H2O2),显色后用酶标仪测在450nm处的吸光度,绘制柱状图,比较各步获得噬菌体抗体跟S1蛋白及BSA的结合性能。
酶联免疫吸附试验的结果如图1所示,比较噬菌体淘筛过程中获得的噬菌体库R0、R2及R3与BSA及S蛋白的结合能力时发现,第二轮淘筛所得噬菌体溶液R2与S蛋白的结合能力与R0相比显著增加,而对BSA的结合能力非常微弱且与R0比较没有显著变化,说明构建的噬菌体展示抗体库中抗新冠病毒S蛋白的抗体得以富集。
三、单克隆抗体的筛选
培养TG-1大肠杆菌至OD600为0.4,取100μL淘筛R2噬菌体抗体库溶出的噬菌体溶液,用于感染200μL的大肠杆菌菌液,37℃孵育30分钟后,将菌液涂布到含有100μg/mL氨卞青霉素,50μg/mL卡那霉素及1%葡萄糖的2YT培养基平板上,37℃过夜培养;次日挑96个菌落接种到96孔的培养板上,37℃培养至OD600为0.4,每个孔内加入M13噬菌体,感染后5000g离心20分钟,去除上清,每孔加入200μL含有100μg/mL氨苄青霉素、50μg/mL卡那霉素及0.1%葡萄糖的2YT培养基,悬浮菌体,30℃/250rpm的速度培养16小时;次日5000g/30分钟离心培养液,分离回收上清,执行酶联免疫吸附试验,检测各单克隆抗体跟S蛋白的结合特异性及结合性能。
酶联免疫吸附试验的操作如下:在96孔酶标板内加入100μL含有病毒S蛋白(1μg/mL)的PBS溶液,4℃过夜,次日弃抗原溶液,加入200μL含有2%脱脂奶粉的溶液,在25℃下孵育2小时,对酶标板进行封闭。用含有0.1%吐温20的PBS溶液洗涤酶标板3次,加入噬菌体溶液,25℃孵育1小时,用PBST溶液洗涤酶标板,加入HRP标记的小鼠抗M13抗体,孵育1小时后,用PBST洗板,加入HRP底物TMBZ(用pH6.0的乙酸钠溶液配制,含1/10000稀释的30%H2O2),显色后用酶标仪测450nm和630nm的吸光度,绘制柱状图,比较利用各克隆制作的噬菌体抗体跟S蛋白及牛血清蛋白的结合性能。
实验表明,有7个微孔颜色较深,其吸光度分别为1.40、1.30、1.35、1.05、1.10、0.80和1.68,将对应微孔的菌体扩大培养后对吸光度1.68的微孔内的抗体抽取质粒并进行基因测序,抗体根据其在实验中微孔板的位置(A行7列)命名为单克隆抗体A7,通过与抗体基因库中登录的抗体氨基酸序列进行比对,没有发现与本发明所述抗体基因相同的序列,因此该抗体为新型抗体。抗体的氨基酸序列详细情况如下所述。
A7抗体重链可变区序列为SEQ ID NO:1,CDRH1序列为SEQ ID NO:2;CDRH2序列为SEQ ID NO:3;CDRH3序列为SEQ ID NO:4;
A7抗体轻链可变区序列为SEQ ID NO:5,CDRL1序列为SEQ ID NO:6;CDRL2序列为SEQ ID NO:7;CDRL3序列为SEQ ID NO:8;
A7-VH(抗体重链可变区):
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAIASSGYYTSYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDTDTFDYWGQGTLVTVSS(SEQ ID NO:1);
CDRH1:GFTFSSYA(SEQ ID NO:2);
CDRH2:IASSGYYT(SEQ ID NO:3);
CDRH3:AKDTDTFDY(SEQ ID NO:4);
A7-VL(抗体轻链可变区):
DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSSPSTFGQGTKVEIKR(SEQ ID NO:5);
CDRL1:QSISSY(SEQ ID NO:6);
CDRL2:AAS(SEQ ID NO:7);
CDRL3:QQANSSPST(SEQ ID NO:8);
四、单克隆抗体的抗原特异性
在96孔酶标板内加入100μL,浓度各为1μg/mL的新冠病毒S蛋白,S-RBD蛋白,及BSA蛋白溶液,4℃过夜,次日弃蛋白溶液,加入200μL 2%脱脂奶粉溶液,在25℃下孵育2小时,对酶标板进行封闭;用含有0.1%吐温20的PBS溶液洗涤酶标板3次后,每孔加入100μL稀释的噬菌体展示抗体溶液,25℃孵育1小时,用PBST溶液洗涤酶标板,加入HRP标记的小鼠抗M13抗体,孵育1小时后,用PBST洗板,加入HRP底物TMBZ(用pH6.0的乙酸钠溶液配制,含1/10000稀释的30%H2O2),显色后用酶标仪测450nm的吸光度,绘制柱状图,比较噬菌体抗体跟包被蛋白的结合性能。
酶联免疫吸附试验的结果如图2所示,A7抗体与S蛋白结合,也与S-RBD蛋白结合,不与包被的BSA结合,说明A7抗体是识别S蛋白RBD区的抗体,与新冠病毒SARS-CoV-2的S蛋白RBD的结合具有特异性。
五、A7-Fab片段的表达与纯化
以淘筛所得A7抗体质粒为模板执行聚合酶链式反应(Polymerase ChainReaction;PCR),反应体系为50μL,反应条件为:94℃变性2分钟后,94℃30秒,55℃30秒,68℃1分钟,反应30个循环后,用1%琼脂糖凝胶检测PCR产物,并回收目的基因片段,纯化PCR产物后,用限制酶EcoRv/HindIII处理PCR,纯化后用Ligation High v.2(东洋纺)将其与用同样的酶处理的pUQ2链接,转化大肠杆菌XL0-Gold,铺板后过夜培养,次日挑取单克隆,菌落PCR,挑含有基因片段的克隆,培养菌落有提取质粒,测序,确认克隆成功。
PCR扩A7抗体重链可变区基因,用AgeI/XhoI处理后按照跟克隆轻链相同的步骤将重链可变区基因克隆到pUQ2,构建Fab表达载体。
用构建成功的重组质粒转化表达宿主菌株SHuffle T7 express,在LB平板培养基上37℃培养14h,挑取单菌落接种到含有终浓度为100μg/mL氨苄青霉素的4mL LB液体培养基中,以200rpm的速度37℃过夜培养,次日将过夜培养的菌液转接至含终浓度为100μg/mL氨苄青霉素的100mL LB培养基中,30℃、200rpm,继续培养3h,测定其吸光度值,当OD600到0.4和0.5之间时,停止培养,向菌液中加入异丙基硫代半乳糖苷(IPTG),使其终浓度为0.4mmol/L,继续在16℃、200rpm条件下培养18小时;
将培养得到的菌液用6000g的转速离心20min,收集菌体,加入含有8mmol/LNa2HPO4·12H2O、47.9mmol/L NaH2PO4·2H2O、300mmol/L NaCl、pH7.0的TALON缓冲液中,在冰水下进行功率为120W,工作时间为3s,间隔时间为2s的超声处理20min,静置30min后,在4℃下进行6000×g,20min的离心,收集上清液;
取100μL TALON Metal Affinity Resin(TAKARA Bio)与9mL上清液于4℃条件用摇床在40rpm的速度下结合30分钟后,将上清混合液加至重力纯化柱,用8mmol/LNa2HPO4·12H2O、47.9mmol/L NaH2PO4·2H2O、300mmol/L NaCl及5mmol/L咪唑、pH7.0的TALONWashing Buffer洗涤纯化柱,之后用8mmol/L Na2HPO4·12H2O、47.9mmol/L NaH2PO4·2H2O、300mmol/L NaCl及500mmol/L咪唑、pH7.0的Elution Buffer将特异性结合的A7-Fab蛋白按洗脱顺序收集样品,对纯化蛋白执行聚丙烯酰胺凝胶电泳(SDS-PAGE),检测纯化蛋白的含量。
实验结果:电泳结果如图3所示,其中泳道M为蛋白Marker(北京索莱宝生物技术有限公司),泳道A7-Fab为收集的抗体Fab片段。箭头所指在28kDa附近出现两条蛋白条带,为Fab片段中的抗体可变区与第一恒定区,抗体的轻链。该结果显示A7-Fab抗体片段得到很好的纯化。
六、酶联免疫吸附试验检测A7-Fab抗体片段的抗原特异性
酶联免疫吸附试验方法原理图如图4所示(图中BSA为牛血清蛋白;S蛋白为新冠病毒S蛋白),在酶标板上包被纯化好的S1蛋白(2μg/mL)及BSA(2μg/mL),4度下孵育过夜,次日将包被溶液倒掉,加入溶解于PBS的2%的脱脂奶粉,对酶标板进行封闭。封闭2小时后洗板,每个孔内加入纯化的A7-Fab抗体溶液,室温下孵育1小时后,再次洗涤酶标板,加入HRP标记的抗组氨酸标签抗体(日本富士试剂有限公司),室温下浮育1小时,洗板后加入底物显色,测450nm时的吸光度。
其结果如图5所示,A7-Fab抗体与实验组(S1蛋白质)反应后显色,其吸光度为1.3,而与对照组(牛血清蛋白BSA)在450nm处的吸光度为0.05,存在显著差异,证明A7-Fab抗体片段能够与新冠病毒S1蛋白特异性结合。
七、酶联免疫吸附试验验证A7-Fab抗体片段阻断ACE2与S1蛋白结合
A7-Fab阻碍ACE2与RBD结合的酶联免疫吸附试验原理示意图如图6所示(图中ACE2-hFc为血管紧张素转化酶(ACE)2与人源抗体Fc段的融合蛋白;RBD为新冠病毒S蛋白的RBD区),在酶标板上包被ACE2-hFc(2μg/mL),4度下孵育过夜,次日将包被溶液倒掉,加入溶解于PBS的2%的脱脂奶粉,对酶标板进行封闭。封闭2小时后洗板,实验组的每个孔内加入RBD(0.5mg/mL)与纯化的A7-Fab抗体片段溶液(5mg/mL),对照组只加入RBD蛋白溶液,室温下孵育1小时后,再次洗涤酶标板,加入兔抗RBD抗体(1mg/mL),室温下孵育1小时后,将抗体溶液倒掉,洗板后加入HRP标记的山羊抗兔抗体(上海生工),室温下浮育1小时,洗板后加入底物显色,测450nm时的吸光度。
实验结果如图7所示,没有加A7-Fab抗体片段的对照组,酶标板微孔样品在450nm的吸光度为1.05,而另外添加了A7-Fab抗体片段的实验组的吸光度为0.54,二者存在显著差异,说明添加A7-Fab后,RBD与ACE2的结合能力下降了49%,证明A7抗体可以有效的阻碍RBD与ACE2的结合,而新冠病毒通过其S1蛋白的RBD区域与细胞表面的ACE2结合后病毒开始感染细胞,即A7抗体具有中和新冠病毒毒性的能力。
序列表
<110> 潍坊医学院
<120> 一种针对新冠病毒SARS-CoV-2棘突蛋白RBD区的单克隆抗体及其应用
<130> 20200904A-7
<141> 2020-09-04
<150> 2020104148681
<151> 2020-05-15
<160> 8
<170> SIPOSequenceListing 1.0
<210> 1
<211> 116
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 1
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Ala Ser Ser Gly Tyr Tyr Thr Ser Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Asp Thr Asp Thr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val
100 105 110
Thr Val Ser Ser
115
<210> 2
<211> 8
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 2
Gly Phe Thr Phe Ser Ser Tyr Ala
1 5
<210> 3
<211> 8
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 3
Ile Ala Ser Ser Gly Tyr Tyr Thr
1 5
<210> 4
<211> 9
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 4
Ala Lys Asp Thr Asp Thr Phe Asp Tyr
1 5
<210> 5
<211> 108
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 5
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Ser Pro Ser
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
100 105
<210> 6
<211> 6
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 6
Gln Ser Ile Ser Ser Tyr
1 5
<210> 7
<211> 3
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 7
Ala Ala Ser
1
<210> 8
<211> 9
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 8
Gln Gln Ala Asn Ser Ser Pro Ser Thr
1 5
Claims (9)
1.一种针对新冠病毒SARS-CoV-2的单克隆抗体,其特征在于:该单克隆抗体与新冠病毒SARS-CoV-2棘突蛋白RBD区特异性结合;包括重链可变区的互补性决定区域CDRH1、CDRH2、CDRH3和轻链可变区的互补性决定区域CDRL1、CDRL2、CDRL3;重链可变区的互补性决定区域CDRH1、CDRH2、CDRH3的氨基酸序列分别如SEQ ID NO:2、SEQ ID NO:3和SEQ ID NO:4所示;轻链可变区的互补性决定区域CDRL1、CDRL2、CDRL3的氨基酸序列分别如SEQ ID NO:6、SEQ ID NO:7和SEQ ID NO:8所示。
2.根据权利要求1所述的一种针对新冠病毒SARS-CoV-2的单克隆抗体,其特征在于:所述单克隆抗体的重链可变区的氨基酸序列为SEQ ID NO:1;所述单克隆抗体的轻链可变区的氨基酸序列为SEQ ID NO:5。
3.一种分离的核酸分子,其特征在于:所述核酸分子编码权利要求1~2中任一项所述的单克隆抗体。
4.一种包括权利要求3所述的核酸分子的表达载体。
5.一种包括权利要求3所述的核酸分子或权利要求4所述的表达载体的宿主细胞。
6.一种非诊断目的的检测新型冠状病毒SARS-CoV-2水平的方法,其特征在于:包括如下步骤:
①提取含有新型冠状病毒SARS-CoV-2的样品;
②将步骤①得到的样品与权利要求1~2中任一项所述的单克隆抗体接触;
③检测样品与抗体的免疫反应。
7.权利要求1~2中任一项所述的针对新冠病毒SARS-CoV-2的单克隆抗体在制备新冠病毒SARS-CoV-2检测产品中的应用。
8.权利要求1~2中任一项所述的针对新冠病毒SARS-CoV-2的单克隆抗体在制备抑制新冠病毒SARS-CoV-2抗体药物中的应用。
9.权利要求1~2中任一项所述的针对新冠病毒SARS-CoV-2的单克隆抗体在制备预防或治疗由新冠病毒SARS-CoV-2引起的肺炎的药物制剂中的应用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020104148681 | 2020-05-15 | ||
CN202010414868 | 2020-05-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112010965A CN112010965A (zh) | 2020-12-01 |
CN112010965B true CN112010965B (zh) | 2021-03-12 |
Family
ID=73392174
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010921453.3A Active CN111961133B (zh) | 2020-05-15 | 2020-09-04 | 一种针对新冠病毒SARS-CoV-2棘突蛋白非RBD区的单克隆抗体及其应用 |
CN202010926533.8A Active CN112010965B (zh) | 2020-05-15 | 2020-09-04 | 一种针对新冠病毒SARS-CoV-2棘突蛋白RBD区的单克隆抗体及其应用 |
CN202010926531.9A Active CN111995676B (zh) | 2020-05-15 | 2020-09-04 | 一种针对新冠病毒棘突蛋白非rbd区的单克隆抗体及其应用 |
CN202010922039.4A Active CN111995675B (zh) | 2020-05-15 | 2020-09-04 | 一种针对新冠病毒SARS-CoV-2棘突蛋白RBD区的单克隆抗体及其应用 |
CN202010926558.8A Active CN112010966B (zh) | 2020-05-15 | 2020-09-04 | 一种针对新冠病毒棘突蛋白非rbd区的单克隆抗体及其应用 |
CN202010944547.2A Active CN111995678B (zh) | 2020-05-15 | 2020-09-10 | 一种针对新冠病毒SARS-CoV-2棘突蛋白RBD区的单克隆抗体及其应用 |
CN202010944546.8A Active CN111995677B (zh) | 2020-05-15 | 2020-09-10 | 一种针对新冠病毒棘突蛋白非rbd区的单克隆抗体及其应用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010921453.3A Active CN111961133B (zh) | 2020-05-15 | 2020-09-04 | 一种针对新冠病毒SARS-CoV-2棘突蛋白非RBD区的单克隆抗体及其应用 |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010926531.9A Active CN111995676B (zh) | 2020-05-15 | 2020-09-04 | 一种针对新冠病毒棘突蛋白非rbd区的单克隆抗体及其应用 |
CN202010922039.4A Active CN111995675B (zh) | 2020-05-15 | 2020-09-04 | 一种针对新冠病毒SARS-CoV-2棘突蛋白RBD区的单克隆抗体及其应用 |
CN202010926558.8A Active CN112010966B (zh) | 2020-05-15 | 2020-09-04 | 一种针对新冠病毒棘突蛋白非rbd区的单克隆抗体及其应用 |
CN202010944547.2A Active CN111995678B (zh) | 2020-05-15 | 2020-09-10 | 一种针对新冠病毒SARS-CoV-2棘突蛋白RBD区的单克隆抗体及其应用 |
CN202010944546.8A Active CN111995677B (zh) | 2020-05-15 | 2020-09-10 | 一种针对新冠病毒棘突蛋白非rbd区的单克隆抗体及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (7) | CN111961133B (zh) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10787501B1 (en) | 2020-04-02 | 2020-09-29 | Regeneron Pharmaceuticals, Inc. | Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments |
CN117003862A (zh) * | 2020-08-19 | 2023-11-07 | 重庆医科大学 | 新冠病毒rbd特异性单克隆抗体和应用 |
CN111909262B (zh) * | 2020-08-19 | 2022-10-04 | 重庆医科大学 | 新冠病毒rbd特异性单克隆抗体和应用 |
CN112062840A (zh) | 2020-09-22 | 2020-12-11 | 石河子大学 | 一种基于新型冠状病毒s蛋白的纳米抗体及其应用 |
WO2022068847A1 (zh) * | 2020-09-29 | 2022-04-07 | 山东博安生物技术股份有限公司 | 一种治疗或预防新型冠状病毒SARS-CoV-2引起的疾病的方法 |
CN112409479B (zh) * | 2020-11-23 | 2022-04-26 | 中国疾病预防控制中心病毒病预防控制所 | 人源抗新冠病毒中和性抗体nCoV-121及其应用 |
CN112574300B (zh) * | 2020-12-02 | 2022-03-08 | 深圳先进技术研究院 | 抗sar-cov-2全人源单克隆抗体及其制法与应用 |
CN114573690B (zh) * | 2020-12-02 | 2023-12-12 | 深圳先进技术研究院 | 抗sar-cov-2全人源单克隆抗体及其制法与应用 |
CN114605527B (zh) * | 2020-12-04 | 2023-07-04 | 中国科学院分子细胞科学卓越创新中心 | 一种抗新型冠状病毒SARS-CoV-2的抗体及其制备方法和用途 |
CN112611868A (zh) * | 2020-12-18 | 2021-04-06 | 厦门大学 | 一种用于磁共振分析方法检测新型冠状病毒的探针及其制备方法 |
CN114685653B (zh) * | 2020-12-31 | 2023-09-12 | 中国科学院分子细胞科学卓越创新中心 | 抗新冠病毒受体结合区域表位中和抗体及其应用 |
CN114716541B (zh) * | 2021-01-05 | 2023-07-21 | 中国科学院分子细胞科学卓越创新中心 | 抗冠状病毒的全人广谱中和抗体76e1及其应用 |
WO2022150809A1 (en) * | 2021-01-05 | 2022-07-14 | Immunome, Inc. | Antibody cocktail against sars-cov-2 spike protein |
CN112394180A (zh) * | 2021-01-19 | 2021-02-23 | 南京立顶医疗科技有限公司 | 一种SARS-CoV-2中和抗体的检测方法、检测试剂盒 |
CN113150129B (zh) * | 2021-01-28 | 2023-02-28 | 四川大学华西医院 | 抗新冠病毒SARS-CoV-2表面S2蛋白的单链抗体及其应用 |
CN112521496B (zh) * | 2021-01-29 | 2022-09-06 | 中国人民解放军空军军医大学 | 特异性结合SARS-CoV-2 Spike RBD的单克隆抗体及其应用 |
CN114805556A (zh) * | 2021-01-29 | 2022-07-29 | 中国科学院上海巴斯德研究所 | 一种针对SARS-CoV-2病毒的中和性抗体 |
CN115109150A (zh) * | 2021-01-31 | 2022-09-27 | 中南大学湘雅医院 | 新型冠状病毒单克隆抗体xy10及其应用 |
WO2022171182A1 (zh) * | 2021-02-10 | 2022-08-18 | 斯微(上海)生物科技股份有限公司 | 一种治疗或者预防冠状病毒病突变株的疫苗试剂 |
CN113009154B (zh) * | 2021-02-25 | 2024-01-30 | 山东莱博生物科技有限公司 | 一步法新型冠状病毒中和抗体磁性微球检测试剂盒及其应用 |
CN112940110B (zh) * | 2021-04-14 | 2022-09-20 | 中山大学 | 抗新型冠状病毒n蛋白单克隆抗体及其应用 |
CN113150135B (zh) * | 2021-04-14 | 2022-09-20 | 中山大学 | 抗新型冠状病毒受体结合区域中和抗体及其应用 |
WO2022241415A1 (en) * | 2021-05-11 | 2022-11-17 | Yale University | Methods for monoclonal antibody generation |
WO2022241200A1 (en) * | 2021-05-14 | 2022-11-17 | Vanderbilt University | Cross-reactive coronavirus antibodies |
CN113307866B (zh) * | 2021-05-26 | 2022-11-11 | 中山大学 | 一种抗体组合物及其应用 |
CN113402603B (zh) * | 2021-06-09 | 2022-05-03 | 陕西理工大学 | 一种抗SARS-CoV-2病毒S1蛋白的禽源单链抗体及其应用 |
CN113416245A (zh) * | 2021-06-15 | 2021-09-21 | 北京华大蛋白质研发中心有限公司 | 一种可结合SARS-CoV-2病毒RBD蛋白的中和抗体及其应用 |
CN113501872B (zh) * | 2021-06-22 | 2022-05-24 | 中国医学科学院病原生物学研究所 | 人源抗新型冠状病毒SARS-CoV-2中和性抗体SK1及其应用 |
CN113563483B (zh) * | 2021-08-09 | 2024-02-02 | 广州明药科技有限公司 | 噬菌体展示新冠病毒衣壳蛋白及应用 |
CN113603786B (zh) * | 2021-08-26 | 2023-05-30 | 深圳市亚辉龙生物科技股份有限公司 | 特异性结合SARS-CoV-2 S蛋白和N蛋白的双特异性抗体 |
CN113929772B (zh) * | 2021-09-30 | 2022-03-25 | 北京康乐卫士生物技术股份有限公司 | SARS-CoV-2中和抗体及其制备方法与应用 |
CN114133447B (zh) * | 2021-10-14 | 2022-07-19 | 河南晟明生物技术研究院有限公司 | 2019-nCoV表面蛋白受体结合区抗体制备方法及用途 |
WO2023072904A1 (en) * | 2021-10-26 | 2023-05-04 | F. Hoffmann-La Roche Ag | Monoclonal antibodies specific for sars-cov-2 rbd |
CN114989291B (zh) * | 2021-11-25 | 2023-01-06 | 浙江安维珞诊断技术有限公司 | 一种靶向RBD的抗SARS-CoV-2全人源化单克隆抗体及应用 |
CN113999301B (zh) * | 2021-12-07 | 2023-07-28 | 江苏中新医药有限公司 | 抗SARS-CoV-2(COVID-19)S蛋白RBD单克隆抗体 |
CN114106164B (zh) * | 2021-12-09 | 2023-05-26 | 杭州旭科生物技术有限公司 | 抗新型冠状病毒s蛋白的单克隆抗体及其应用 |
WO2023125964A1 (en) * | 2022-01-03 | 2023-07-06 | Versitech Limited | Neutralizing antibodies against covid-19 and methods of use thereof |
CN115819565A (zh) * | 2022-06-06 | 2023-03-21 | 百斯医学诊断科技(北京)有限公司 | 新型冠状病毒Omicron突变株特异性抗体及其应用 |
CN115894675B (zh) * | 2023-02-03 | 2023-11-14 | 康复大学(筹) | 新冠病毒SARS-CoV-2核衣壳蛋白单克隆抗体及其应用 |
CN117551191A (zh) * | 2023-11-15 | 2024-02-13 | 江苏省疾病预防控制中心(江苏省公共卫生研究院) | 针对SARS-CoV-2的单克隆抗体 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111122879A (zh) * | 2020-03-26 | 2020-05-08 | 珠海丽珠试剂股份有限公司 | 新型冠状病毒重组抗原的包被液、预处理方法及应用和产品 |
CN111157723A (zh) * | 2020-02-16 | 2020-05-15 | 广西中医药大学附属瑞康医院 | 一种新型冠状病毒的快速检测盒 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1648927A1 (en) * | 2003-07-21 | 2006-04-26 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Soluble fragments of the sars-cov spike glycoprotein |
JP2008529504A (ja) * | 2005-02-08 | 2008-08-07 | ニューヨーク ブラッド センター | 重症急性呼吸器症候群関連コロナウイルスに対する中和モノクローナル抗体 |
EP2242768A4 (en) * | 2008-01-17 | 2012-03-14 | Humabs Llc | CROSS-NEUTRALIZATION OF HUMAN MONOCLONAL ANTIBODIES AGAINST SARS-COV AND METHODS FOR THEIR APPLICATION |
CN110951756B (zh) * | 2020-02-23 | 2020-08-04 | 广州恩宝生物医药科技有限公司 | 表达SARS-CoV-2病毒抗原肽的核酸序列及其应用 |
CN111592594B (zh) * | 2020-03-13 | 2022-05-10 | 北京大学 | 一种抗新型冠状病毒的单克隆抗体及其应用 |
CN111690059B (zh) * | 2020-06-19 | 2022-03-08 | 武汉生物制品研究所有限责任公司 | 一种抗SARS-CoV-2的单克隆抗体1D7 |
CN111995672B (zh) * | 2020-07-20 | 2022-05-20 | 江苏集萃医学免疫技术研究所有限公司 | 冠状病毒sars-cov-2 s蛋白特异性抗体及其用途 |
CN115477698A (zh) * | 2020-08-19 | 2022-12-16 | 重庆医科大学 | 新冠病毒rbd特异性单克隆抗体和应用 |
-
2020
- 2020-09-04 CN CN202010921453.3A patent/CN111961133B/zh active Active
- 2020-09-04 CN CN202010926533.8A patent/CN112010965B/zh active Active
- 2020-09-04 CN CN202010926531.9A patent/CN111995676B/zh active Active
- 2020-09-04 CN CN202010922039.4A patent/CN111995675B/zh active Active
- 2020-09-04 CN CN202010926558.8A patent/CN112010966B/zh active Active
- 2020-09-10 CN CN202010944547.2A patent/CN111995678B/zh active Active
- 2020-09-10 CN CN202010944546.8A patent/CN111995677B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111157723A (zh) * | 2020-02-16 | 2020-05-15 | 广西中医药大学附属瑞康医院 | 一种新型冠状病毒的快速检测盒 |
CN111122879A (zh) * | 2020-03-26 | 2020-05-08 | 珠海丽珠试剂股份有限公司 | 新型冠状病毒重组抗原的包被液、预处理方法及应用和产品 |
Non-Patent Citations (1)
Title |
---|
Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses;Shibo Jiang等;《Trends in Immunology》;20200402;第41卷(第5期);全文 * |
Also Published As
Publication number | Publication date |
---|---|
CN111995675B (zh) | 2021-03-23 |
CN111995677B (zh) | 2021-03-23 |
CN112010966B (zh) | 2021-03-19 |
CN111961133A (zh) | 2020-11-20 |
CN112010966A (zh) | 2020-12-01 |
CN111961133B (zh) | 2021-03-23 |
CN111995676A (zh) | 2020-11-27 |
CN111995678B (zh) | 2021-03-09 |
CN111995678A (zh) | 2020-11-27 |
CN111995677A (zh) | 2020-11-27 |
CN111995676B (zh) | 2021-03-09 |
CN111995675A (zh) | 2020-11-27 |
CN112010965A (zh) | 2020-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112010965B (zh) | 一种针对新冠病毒SARS-CoV-2棘突蛋白RBD区的单克隆抗体及其应用 | |
CN113429478B (zh) | 针对新冠病毒SARS-CoV-2的单克隆抗体H9 | |
US11661448B2 (en) | Nano-antibody and its application based on SARS-CoV-2 S protein S1 subunit | |
US11820811B2 (en) | Nano-antibody and its application based on SARS-CoV-2 S protein | |
CN113336844A (zh) | 一种靶向新冠病毒n蛋白的鲨鱼单域抗体及其制备方法和应用 | |
WO2022061594A1 (zh) | 新型冠状病毒(sars-cov-2)刺突蛋白结合分子及其应用 | |
CA3109433A1 (en) | Ns1-binding protein and uses thereof | |
US20240117012A1 (en) | Anti-sars-cov-2 antibody | |
CN114773464B (zh) | 一种针对新冠病毒omicron株S蛋白的单域抗体VHH-2及编码序列和应用 | |
CN114773465B (zh) | 一种针对新冠病毒omicron株S蛋白的单域抗体VHH-3及编码序列和应用 | |
CN114605555B (zh) | 一种抗新型冠状病毒SARS-CoV-2的双特异中和抗体及其应用 | |
WO2021221136A1 (ja) | 抗SARS-CoV-2抗体 | |
WO2021221137A1 (ja) | 抗SARS-CoV-2抗体を用いた医薬品及び検査キット | |
CN115894675B (zh) | 新冠病毒SARS-CoV-2核衣壳蛋白单克隆抗体及其应用 | |
CN110845607B (zh) | 一种h1n1流感病毒抗体及其在h1n1病毒超微量检测方面的应用 | |
CN113943367A (zh) | 针对新型冠状病毒的单域抗体、试剂盒和药物 | |
CN104650224B (zh) | 一种针对sea的纳米抗体及其编码序列与应用 | |
CN112940081A (zh) | 可特异性结合新型冠状病毒核衣壳蛋白的多肽分子及制备方法 | |
CN114773463A (zh) | 一种针对新冠病毒omicron株S蛋白的单域抗体VHH-1及编码序列和应用 | |
CN117777280A (zh) | 新型冠状病毒SARS-CoV-2广谱中和单域抗体及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |